Nykode Therapeutics ASA is a clinical-stage biopharmaceutical company which engages in discovering and developing of novel immunotherapies. The company is headquartered in Oslo, Oslo and currently employs 75 full-time employees. The company went IPO on 2020-01-27. Nykode uses its vaccine technology platform to generate therapeutics in disease indications with unmet medical need. The firm develops next generation vaccines for clinical use, based on a deep understanding of immunological principles. Nykode Therapeutics’ main product candidates are VB10.16 and VB10.NEO. VB10.16 is a therapeutic cancer vaccine against HPV16-related cancers. VB10. NEO is a therapeutic cancer neoantigen vaccine. The firm also has two universal COVID-19 vaccine candidates in development.
Follow-Up Questions
What is the price performance of VACBF stock?
The current price of VACBF is $0.294, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Nykode Therapeutics ASA?
Nykode Therapeutics ASA belongs to Biotechnology industry and the sector is Health Care
What is Nykode Therapeutics ASA market cap?
Nykode Therapeutics ASA's current market cap is $96.0M
Is Nykode Therapeutics ASA a buy, sell, or hold?
According to wall street analysts, 4 analysts have made analyst ratings for Nykode Therapeutics ASA, including 0 strong buy, 0 buy, 3 hold, 4 sell, and 0 strong sell